Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease Treated With Nebulized Arformoterol Following a Respiratory Event
Chronic Obstructive Pulmonary Diseases - United States
doi 10.15326/jcopdf.6.4.2019.0127
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2019
Authors
Publisher
COPD Foundation